UNSPSC 51283006: Clindamycin phosphate

This classification denotes a lincosamide antibiotic with the molecular formula C18H34ClN2O8PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EH6D7113I8, chemically known as l-threo-.alpha.-d-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, 2-(dihydrogen phosphate), (2s-trans)-, but more generally known as clindamycin phosphate, which bears US NIH Compound Identifier 29029.

UNSPSC 51283006 Clindamycin phosphate is a Commodity code that, based on recent state and local solicitation activity, does not align with the actual procurement work being tagged under it. The recent opportunities posted under this code include naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), medical and first aid supplies for emergency response (City of Tampa), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations involve clindamycin phosphate, an antibiotic pharmaceutical, and they span vastly different commodity families—naloxone (an opioid antagonist), emergency medical supplies, and broad pharmacy benefit programs. The code shows significant tagging inconsistency with actual procurement scope.

Activity under this code appears concentrated among state health agencies, county health departments, and cooperative purchasing vehicles rather than individual municipalities or school districts, though the mismatch between code and solicitation content limits reliable characterization. Recent opportunities span Florida, Texas, Minnesota, and Oregon, though the geographic spread reflects the location of issuing bodies rather than coherent pharmaceutical procurement activity aligned with clindamycin. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies with an estimated contract amount of $700,000.00 (due March 13, 2026), the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (due April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). Vendors should verify actual commodity classifications for targeted solicitations before pursuing opportunities nominally tagged to this code.